Objective: In many cases where Huntington disease (HD) is suspected, the genetic test for HD is negative: these are known as HD phenocopies. A repeat expansion in the C9orf72 gene has recently been identified as a major cause of familial and sporadic frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Our objective was to determine whether this mutation causes HD phenocopies.
Huntington disease (HD) is an autosomal dominantly inherited neurodegenerative condition typically characterized by a triad of psychiatric, movement, and cognitive impairment. In many cases in which HD is suspected clinically, patients lack the CAG repeat expansion that causes HD. [1] [2] [3] [4] Such individuals are said to have HD phenocopy syndromes or HD-like disorders. 5 Wild and Tabrizi 3 reviewed genes identified in different HD phenocopy cohorts to determine that spinocerebellar ataxia 17 (TBP) accounts for 1.1%, Huntington disease-like 2 (HDL2) for 0.7%, Friedreich ataxia (JPH3) for 0.35%, and inherited prion disease (PRNP) for 0.24% of HD phenocopies. Testing for these mutations is now routinely performed; however, the majority of HD phenocopy patients still do not attain a formal genetic diagnosis.
In 2011, an expanded hexanucleotide repeat in the C9orf72 gene was identified in large kindreds with frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). 6, 7 This expansion is recognized as the most common genetic cause of ALS and FTLD in many, but not all, populations. [6] [7] [8] [9] The mutation is intronic, in a highly conserved gene, 6, 10 which has homology with the DENN-like superfamily, suggesting a role as regulator of membrane traffic, [10] [11] [12] and which may be involved in other neurologic conditions. 13 Several hundred thousands of repeats have been documented in pathogenic expansions. 14 Elucidating the pathogenic mechanism of this expansion has generated much interest; several non-mutually exclusive possibilities exist. 6, [15] [16] [17] [18] [19] In this study, we undertook to examine whether the C9orf72 expansion causes HD phenocopy clinical presentations and hence whether testing for it should be considered in the routine genetic workup of this patient group.
METHODS Case ascertainment. As previously described, 20 subjects were classified as having HD phenocopy syndromes on the basis of a clinical presentation consistent with HD when assessed by an experienced neurologist or neurogeneticist, and a negative test for the expanded CAG repeat in the HTT gene that causes HD (,36 repeats). At the Neurogenetics Unit of the National Hospital for Neurology and Neurosurgery (NHNN), London, UK, 63.5% of diagnostic HD tests (those done on symptomatic patients) are negative for HD. A cohort of 514 HD phenocopy patients who underwent negative diagnostic genetic testing for HD at NHNN were identified. The average age at onset in this cohort was 48.8 years in those with precise onset data (SD 19.3, n 5 176). Three hundred subjects were seen at NHNN, 214 at other hospitals. Of those seen at NHNN, 45.3% were seen by a movement disorders consultant, 15.3% by a cognitive disorders consultant, 14.3% by a neurogenetics consultant, and 25% by other consultant neurologists.
Clinical summaries were reviewed for all cases, and all available clinical case notes reviewed for cases positive for the C9orf72 expansion mutation. Demographic data, family history, examination findings, first symptoms, and age at onset were recorded. Where available, neuropsychometry reports were reviewed, and additional investigations were documented including electrophysiologic assessments, MRI, CSF, and tissue biopsies. HTT CAG repeat length was recorded. Fisher exact test (Stata software) was used to examine the relationship between the presence of particular clinical signs and gene test outcome.
All C9orf72-positive cases were given a modified Goldman score, 21, 22 which was used to quantify the strength of the autosomal dominant family history.
Standard protocol approvals, registrations, and patient consents. Ethical approval to undertake these analyses was given by the local NHNN/ION ethics committee. Informed consent for genetic studies was obtained from all participants.
Repeat primed PCR. To test for the presence of an expansion at C9orf72, repeat primed PCR was carried out as previously described. 7 Fragment length analysis was undertaken on an ABI (Carlsbad, CA) 3730xl automated sequencer. Analysis of repeat primed PCR electropherograms was performed using Peak Scanner v1.0 (ABI). Expansions with a characteristic sawtooth pattern were identified and put forward for Southern blotting.
Rs3849942 genotyping. The surrogate marker rs3849942, reported to be associated with an increased risk of mutation, 6, 14 was genotyped by allelic discrimination using the 59 nuclease assay in conjunction with minor groove binding probes. The assay was performed on the SDS7500 Fast Real-Time PCR system (ABI) and genotyping calls were made using software v2.0.6.
Southern hybridization. A recently described Southern hybridization protocol was used. 14 This combined the use of an oligonucleotide (GGGGCC) 5 probe that targets multiple sites within the expansion and genomic DNA (gDNA) digested with 2 frequently cutting restriction endonucleases whose sites closely flanked the repeat region. Hexanucleotide repeat number was estimated by interpolation of autoradiographs using a plot of log 10 base pair number against migration distance, which was created in Microsoft (Redmond, WA) Excel.
RESULTS Genetic analyses. Of the 514 HD phenocopy cases screened, 10 probands (1.95%, 95% confidence interval [CI] 1-4) were positive for the C9orf72 expansion, making this mutation the most common identified cause of HD phenocopy syndromes in a UK cohort. 20 Genotyping of the C9orf72-positive cases was consistent with all previous reports in that these individuals were either heterozygous or homozygous for the rs3849942 A allele 6 (table 1). No C9orf72-positive cases had intermediate-sized HD CAG repeats in the huntingtin gene, and there was no correlation between the larger HD normal allele and age at onset.
Southern hybridization (table 1 and figure 1) of 8/10 subjects for whom there was sufficient DNA demonstrated that the size of expansion in this HD phenocopy case series was not significantly different from that found in series with other clinical presentations of the C9orf72 expansion. 14 There was no significant difference in expansion size between those with and without chorea/dystonia.
Of the entire cohort, 19.5% had a family history of similar neurodegenerative disease, whereas 70% of C9orf72-positive cases had a positive family history (see Goldman scores, table 1). These results suggest that there is a predominance of those with family history, but sporadic C9orf72-positive cases may be possible.
Clinical features of C9orf72 expansion gene carriers. The mean age at onset was 42.7 years (range 8-60). Early psychiatric and behavioral problems were common; they were the first recorded symptoms in 6 of the cohort. Depression occurred in 4, obsessions in 2, apathy in 2, and psychosis in 2 cases (table 2) .
Movement disorders were a prominent feature in this cohort: 3 exhibited chorea, 4 dystonia, 4 myoclonus, and 3 tremor. Six of the 10 subjects had rigidity and 5 bradykinesia. Chorea was observed periorally in 1, was generalized with predominant head and arm involvement in 1, and in the left arm and leg in another. Of the 4 subjects with dystonia, 3 were observed to have torticollis. In 4 of the 10 subjects, upper motor neuron signs were noted; lower motor neuron signs were not observed in any.
Cognitively, executive dysfunction was noted in 6 subjects, and memory impairment was present in 6; in subject 6, for whom limited history was available, "cognitive impairment" was noted.
Of 8 cases with available MRI reports, 4 had generalized atrophy.
Case 4 was found to be homozygous for the C9orf72 expansion mutation and has been described in detail in Fratta et al. 23 Comparisons between C9orf72-positive cases and the rest of the HD phenocopy cohort. To examine whether there are particular HD phenocopy cases in whom C9orf72 testing should be prioritized, we compared the frequencies of symptoms and signs between the whole cohort and those with the expansion (table 3) .
Fisher exact test was performed to investigate association between each clinical feature and the outcome of the C9orf72 genetic test. The presence of cognitive and psychiatric features, and some movement disorder features (dystonia, bradykinesia/rigidity, tremor, myoclonus, and upper motor neuron features), were significantly associated with a positive C9orf72 test (table 3) . Though there may be some degree of ascertainment bias as more clinical detail was recorded for positive cases, it remains clear that many symptoms characteristic of HD phenocopies are associated with a C9orf72 gene expansion.
An illustrative case. Case 5, a right-handed Caucasian woman, had a normal birth and development and was university educated. She worked in a professional job and was well until a sudden bereavement when she was 50, after which she became depressed.
At around 55 years, increasing fatigue was noted, and she had her first falls, initially backwards. She stopped working and developed a change in personality with decreased interest in her environment and childlike behavior. She developed hypophonia and slurred speech.
By 58 years, she was having difficulty mobilizing, and within 12 months went from independent living to being mute, profoundly bradykinetic, and requiring a hoist to transfer. She developed dystonic posturing of her feet and hands, and involuntary movements and a tremor in her lower limbs.
In her family history, her father died of dementia without motor problems aged 69 years.
She was admitted to the hospital for investigation at age 60 years. On examination, there was akinetic mutism with marked axial rigidity. There was left laterocollis, minor right torticollis, perioral movements, and occasional right cheek movements. There was broken pursuit and slow broken saccades. There was moderate rigidity with spasticity in the upper limbs and severe rigidity in An unusual case. Case 7, a right-handed Caucasian man, had a normal birth and early development. At age 3, in nursery school, it was noted that he did not mix well with the other children. At primary school, age 5, he was found to have slight difficulties with writing; at age 6, he was unable to follow basic lessons. Soon thereafter he was seen by an educational psychologist and was diagnosed with moderate learning difficulties and was transferred to special needs school. By age 8 years, he had abnormal movements under stress, particularly affecting his hands and head. These became more prominent by 21 years of age, when they affected his walking. Occasionally his right leg was noted to jerk uncontrollably from under him, and he had some falls. The "fidgeting" and jerking movements of hands and neck deteriorated. From 21 years on, he had increased frustration and aggression.
His parents are nonconsanguineous. His maternal grandmother died of motor neuron disease; both parents were well.
At age 23 years, he was admitted to the hospital for investigation. Gait was slightly broad-based, with both arms tending to hold slightly dystonic postures, particularly on the right. There was decreased arm swing, nuchal more than axial rigidity, unsteadiness on heel-toe walking, and Romberg test was negative. Eye movements were abnormal, with poor gaze initiation, impaired pursuit, saccadic hypometria with head thrusts, and reduced vertical upgaze. There was generalized chorea with mainly head and arm involvement, oro-buccal chorea, myoclonic movements of the head and neck, and some additional dystonic elements with mild bradykinesia. In the limbs, there were prominent irregular myoclonic jerks, exacerbated by movement and stimuli. Reflexes and sensation were normal. MMSE score was 20/28. On neuropsychological examination, the Wechsler Adult Intelligence Scale-Revised score was within the defective range, consistent with learning difficulties. There was evidence of memory impairment for visual and verbal memory.
MRI scan showed one small lacune. Nerve conduction studies and EMG were normal. EEG revealed a diffuse and nonspecific excess of theta activity with a trace of alpha-like activity. Although the bursts of high-voltage slow activity had a bursting paroxysmal quality, no definite epileptiform activity was seen. See supplementary data, case 2, for more details of clinical investigations undertaken. DISCUSSION HD is the most common genetically determined neurodegenerative disease, with a prevalence of at least 12.4 per 100,000 people, 24 but in those in whom HD is suspected but a CAG repeat expansion in HTT is absent, attaining genetic diagnosis has been rare (2.8% 20 ). We present data demonstrating that the C9orf72 expansion is the most common identified genetic cause of HD phenocopy presentations in a UK cohort, with a prevalence of 1.95% (95% CI 1-4).
HD is an autosomal dominant condition, classically presenting with a triad of movement, cognitive, and psychiatric symptoms. However, there is clinical heterogeneity, particularly early in disease, and not all characteristic features may be apparent: 90% of adults with HD develop chorea, but the clinical spectrum is broad, including parkinsonian akinetic-rigid syndromes and relatively pure dystonic, ataxic, and psychiatric presentations. 25 Around 8% of patients with HD present without an apparent family history of HD. 26 Because of this clinical diversity, it is accepted 3,20 that any definition of HD phenocopy syndromes needs to encompass not only the classical triad of HD but also syndromes having a major degree of overlap with HD, and those without a known autosomal dominant family history. Those patients with a clear family history of HD and with classical manifest HD are more likely to have HD; however, many patients seen by neurologists do not present in such a clear-cut manner. Our cohort is composed of patients seen by experienced neurologists in whom the diagnosis of HD was considered, thus it reflects clinical reality. It is United Kingdom-based, and given that United Kingdom-based cohorts have similar ethnic descent to other European, Australian, and North American cohorts, our findings are likely to be representative of cohorts from these areas. In patients of African origin (particularly southern Africans), JPH3 expansion remains the most common cause of HD-like presentations. 27 Identifying the causes of HD phenocopy syndromes is of importance to the diagnosis and management of patients with these presentations, as well as the counseling of such individuals and their relatives in matters of genetic testing, life choices, and reproduction. 3 Diagnostic tests for this novel mutation have recently become available. Many symptoms characteristic of HD were associated with the subject being C9orf72-positive; given this, and the high frequency of C9orf72 expansion among HD phenocopies, it should be tested for in all HD phenocopy cases. In the future it is likely that multigene "disease panels" will supersede the need for sequential genetic testing; however, since C9orf72, like many other causes of HD phenocopies, is an expansion mutation, it will remain important for the clinician to be aware of which tests are most appropriate for different patients and request them accordingly. We propose a revised clinico-genetic algorithm for the investigation of HD phenocopy cases in figure 2 .
The effects of the C9orf72 expansion are known to be both clinically and pathologically varied 28 and it is the major cause of both familial and sporadic ALS and FTLD, which are themselves phenotypically heterogeneous conditions. Parkinsonism, particularly rigidity and bradykinesia, has been previously noted in C9orf72-positive individuals [29] [30] [31] ; the C9orf72 mutation has been found in some cohorts of patients with Parkinson disease 32 and not others. 30, 33, 34 In this study we have demonstrated that the clinical phenotypes caused by C9orf72 expansion mutations are broader than previously noted. It can present with a movement disorder including chorea, dystonia, myoclonus, and tremor. The combination of movement disorder, cognitive decline, and psychiatric and behavioral problems, often with a family history of similar problems, explains why C9orf72-positive cases can have a presentation very similar to HD. It is notable that ALS-type symptoms were relatively infrequent in the HD phenocopy C9orf72 cases: none had lower motor neuron signs, while 40% had upper motor neuron signs. By contrast, symptoms more characteristic of FTLD such as cognitive impairment were much more prevalent, suggesting that there is more overlap between the HD-like and FTLD-like cases.
The average age at onset for C9orf72 in published reports is around 57 years 7, 9, 31, 35 ; in this study, it is lower at 42.7 years (range 8-60), suggesting that the condition should be considered in the differential diagnosis not only in a wider range of clinical presentations, but in a wider demographic group than previously identified.
We examined whether the difference in phenotype could be accounted for by a different size of expansion by Southern hybridization: the size of expansion in our HD phenocopy cohort was not significantly different from that of other cohorts. 14 Furthermore, among the 8 C9orf72-positive subjects examined here, there is no statistically significant association between expansion size and age at onset. Case 7, who had motor onset at 8 years, underwent wholeexome sequencing; no large-scale structural abnormalities were detected. An important caveat is that there is evidence of reduced penetrance of the C9orf72 expansion given that the population frequency of C9orf72 expansion is 1 in 691 14 in the UK population, so there is a small possibility of false-positives accounting for one or more of these unusual presentations of C9orf72 mutations.
Among the 10 HD phenocopy C9orf72 cases, there was a tendency for those with chorea and dystonia to have younger ages at onset than those without them: the average age at onset of subjects with chorea/dystonia in this cohort is 28.3, whereas the average age at onset of those without them is 54.8 (p 5 0.019, independent samples Mann-Whitney U test). This may reflect our ascertainment criteria, since HD phenocopy patients are more likely to be young and have movement disorders than patients with FTLD or ALS. However, it is possible that the C9orf72 expansion with these motor symptoms manifests with earlier onset.
Incomplete penetrance has been previously suggested in C9orf72 expanded individuals, 13, 31, 36 which has important implications for genetic testing. In this case series there was no reported family history in 3 cases, and case 7's family history is compatible with incomplete penetrance-the subject's maternal grandmother had motor neuron disease, but the mother was well.
We present a large case series that not only demonstrates that the C9orf72 expansion is the most frequent cause of HD phenocopy presentations in this UK-based population, but also that the phenotype of the C9orf72 Figure 2 Algorithm for the investigation of Huntington disease phenocopy cases
Proposed clinico-genetic algorithm for the workup of Huntington disease (HD) phenocopy patients, highlighting key diagnoses to be considered. DRPLA 5 dentatorubral-pallidoluysian atrophy; HDL2 5 Huntington disease-like 2; NBIA 5 neurodegeneration with brain iron accumulation; SCA 5 spinocerebellar ataxia.
encompasses a diversity of movement disorders, and a younger age at onset than previously recorded.
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